Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs

Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs

BERKELEY, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing...

Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs - PressReach

BERKELEY, Calif., July 31, 2026 (GLOBE NEWSWIRE) — Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of an Option Agreement (the “Agreement”) which provides Profusa the right and option, but not the obligation, subject to satisfaction of the conditions described below, to acquire G3 Vision Labs, Inc. (“G3”) and its subsidiaries, Med Screen Laboratories Inc., Dominion …

Profusa Inc. (PFSA) Stock: Drops as G3 Deal Hinges on $30M Financing

TLDR Profusa stock drops after hours as the G3 acquisition faces key conditions. The G3 deal requires at least $30 million in secured financing before completion. G3’s unaudited 2025 revenue estimate of $111 million supports the deal value. Shareholder...